Header Logo

Connection

CHRISTIE BALLANTYNE to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Cost-Benefit Analysis.
CHRISTIE BALLANTYNE
Connection Strength
0.349
Cost-Benefit Analysis
  1. Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Netw Open. 2022 02 01; 5(2):e2148172.
    View in: PubMed
    Score: 0.152
  2. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
    View in: PubMed
    Score: 0.123
  3. Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States. J Am Heart Assoc. 2024 01 02; 13(1):e032413.
    View in: PubMed
    Score: 0.043
  4. Maximizing the cost-effectiveness of lipid-lowering therapy. Arch Intern Med. 1998 Oct 12; 158(18):1977-89.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.